
G-Dragon, Le Sserafim, Babymonster push on with overseas concerts amid Covid-19 surge in Asia
Babymonster performs during its world tour "Hello Monsters" in Singapore on May 17. - Photo: YG Entertainment
SEOUL: Despite the recent surge in the number of Covid-19 cases across parts of Asia, K-pop stars, including G-Dragon, Le Sserafim and Babymonster, are pressing ahead with their overseas concerts.
According to the Korea Disease Control and Prevention Agency (KDCA) on Monday (June 2), countries including China, Thailand and Singapore have recently reported a notable increase in Covid-19 cases.
While the situation in Korea remains relatively stable, the agency warned that a summer resurgence is possible due to international travel and regional outbreaks.
The NB.1.8.1 variant — now dominant in the affected countries — is known for its strong transmissibility and immune-evasive properties, although its severity and fatality rate remain relatively low.
The KDCA is advising high-risk travelers to these countries to get vaccinated before departure.
G-Dragon. - Photo: Galaxy Corporation
G-Dragon of Big Bang is currently on his 'Ubermensch' world tour, performing across nine Asian cities including Taipei, Kuala Lumpur, Jakarta, Hong Kong and Bangkok as well as Sydney and Melbourne in Australia. He is slated to perform in Macao for three concerts starting June 7.
Asked whether shows in Southeast Asia might be canceled due to COVID-19 concerns, his agency Galaxy Corporation told The Korea Herald, 'We don't know at this point.'
G-Dragon recently called off his "G-Dragon Media Exhibition: Ubermensch" in Shanghai, which was originally scheduled to run from May 30 to June 22.
While the agency cited 'unforeseen circumstances beyond our control' as the reason for the cancellation, the uptick in COVID-19 cases in China is widely suspected as a contributing factor.
Babymonster, also on an Asia tour, wrapped up its 'Hello Monsters' concerts in Singapore and Hong Kong in May and is preparing for its final Southeast Asian stop in Bangkok from June 7-8.
YG Entertainment confirmed it has no plans to postpone or cancel the shows.
'We're monitoring the situation closely, but the outbreak is limited to certain regions. Everything is proceeding as planned,' a YG official told The Korea Herald on Wednesday.
Le Sserafim is scheduled to perform in Taiwan and Hong Kong in July, followed by concerts in the Philippines, Thailand and Singapore in August as part of its 'Easy Crazy Hot' world tour. Source Music's parent company, Hybe, also confirmed that all shows will proceed as scheduled.
JYP Entertainment's acts — Niziu, Nmixx and Xdinary Heroes — are also expected to hold small-scale performances in Hong Kong, Macao and Taiwan, respectively, in the second half of the year, with no changes announced.
An industry official noted that unless governments issue specific warnings or event restrictions, K-pop agencies are unlikely to take unilateral action regarding concert postponements.
'There aren't any government guidelines like we saw during the height of the pandemic, so it's hard for companies to take preemptive action on their own,' one agency source said.
Another industry official echoed the sentiment: 'Without national-level advisories, it's difficult for agencies to make those decisions independently.' - The Korea Herald/ANN
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
2 hours ago
- Malaysian Reserve
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. MISSISSAUGA, ON, June 6, 2025 /CNW/ – GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country. Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap. Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies. 'As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges,' said Michelle Horn, Country Medical Director, GSK Canada. 'Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred.' Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include: Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations Leveraging digital health tools and technology to support clinical decision-making and personalized outreach Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services Implementing science methodologies to ensure successful and scalable solutions across regions and populations This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies. 'As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries,' said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. 'PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally.' Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also: Provide funding to support new interdisciplinary projects with direct policy and practice implications Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention Establish a network of community pharmacies engaged in research, data collection and pilot projects Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development. 'Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare,' added Michelle Horn, Country Medical Director, GSK Canada. 'We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health.' Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application. PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation. About the University of Waterloo School of PharmacyThe School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes. About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.


The Star
3 hours ago
- The Star
Elon Musk is not the father of my kids: Ayumi Hamasaki sets the record straight
Ayumi Hamasaki went on social media earlier this week to quash rthe umours that Elon Musk is her baby daddy. Photos: Ayumi Hamasaki/Instagram, AP Japanese pop diva Ayumi Hamasaki would like you to know that Elon Musk is not the father of her two children, thank you very much. This misunderstanding stemmed from a New York Times article in late May, where one of Musk's ex-flames, Ashley St. Clair, said that the American billionaire had fathered the child of "a Japanese pop star". Some netizens believe it's Japanese TV personality Tenka Hashimoto, while others suspect it's 46-year-old Hamasaki. For the record, Musk, 53, has already fathered 14 children with several different women. Hamasaki went on social media earlier this week to quash the rumours. 'I've been keeping an eye on this, and I guess it's time for me to speak up. Elon Musk is not the father of [either of] my kids," the singer said on Instagram on June 2. The J-pop star, who has been married twice, has two children aged six and four. She has remained tight-lipped about their father's identity. Hamasaki is more amused than upset at the rumours. She said: "I mean, I can understand if someone were to think it seems like the sort of thing I'd do. Even my mum laughed when she heard the rumours, saying, 'This seems kind of Ayu-like'." Hamasaki added that she felt the need to set the record straight for the sake of her children. 'Setting aside my personal image, when my kids are old enough to start Googling things I don't want them to run into the rumours and think they're true, so I'm firmly denying them," she said.


Hype Malaysia
5 hours ago
- Hype Malaysia
EXO's D.O To Return To Malaysia This August; Tickets & Seating Plan Announced
Get ready, Malaysia! One of Korea's most soulful and captivating voices is returning to our shores. Doh Kyung Soo (도경수), also known as D.O (디오), the main vocalist of global K-pop powerhouse EXO, is embarking on his highly anticipated first-ever solo concert tour: '2025 DOH KYUNG SOO ASIA CONCERT TOUR ', with a special stop in Kuala Lumpur! Following the phenomenal success of his sold-out fan concert in KL last year, where the singer charmed fans with his warmth, wit, and stunning vocals, the memory of that magical night still lingers in the hearts of many. Now, the idol returns with an upgraded experience—his first full-length solo concert, promising a night filled with music, memories, and unmatched vocal brilliance. Titled '', this upcoming concert tour marks a major milestone in D.O's artistic journey. Known for his deep emotional resonance, cinematic stage presence, and impeccable vocal control, D.O will take fans on an immersive musical experience that reflects his personal evolution and artistry beyond EXO. Without any further ado, here are the confirmed details of the KL show: 2025 DOH KYUNG SOO ASIA CONCERT TOUR Date: 30th August 2025 (Saturday) 30th August 2025 (Saturday) Time: 6pm 6pm Venue: Axiata Arena, Bukit Jalil, Kuala Lumpur Axiata Arena, Bukit Jalil, Kuala Lumpur Organiser: UnUsUaL Entertainment UnUsUaL Entertainment Ticketing: RM988 (CAT1), RM888 (CAT2), RM688 (CAT3), RM488 (CAT4) As seen in the poster above, fans will get to enjoy certain benefits depending on the tickets purchased. Tickets go on sale via BookMyShow on 9th June 2025 (Monday) at 12pm. This is more than a concert—it's a celebration of D.O's voice, vision, and heartfelt connection with fans. Don't miss the chance to be part of this landmark moment in Malaysian K-pop history. Are you ready to catch the EXO member live on stage again? Which song are you looking most forward to seeing him perform? While we wait, let's enjoy his latest single '밤에 내린 눈 (Snowfall at Night)'. What's your Reaction? +1 0 +1 0 +1 0 +1 0 +1 0 +1 0